38
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medrx Co
Its shares trade on Tokyo Stock Exchange under the ticker 4586.T. It has been listed since 13 February 2013. In the fiscal year to 31 December 2025, it reported revenue of ¥128.1m and a net loss of ¥937.4m. At that date it held total assets of ¥2.16bn and shareholders' equity of ¥2.05bn.
Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. The company is headquartered in Higashikagawa-Shi, Kagawa-Ken. The company went IPO on 2013-02-13. The firm produces new medicines based on percutaneous absorption formulation technology. The firm has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Feb 2013
- Employees
- 22
- Website
- medrx.co.jp ↗
Leadership
Pay as last reported
- Mr. Masayoshi MatsumuraChairman of the Board, since 2002
- Mr. Yonehiro MatsumuraPresident, Chief Executive Officer, President of Subsidiary, Representative Director, since 2003
- Mr. Ken FujiokaDirector of Business Administration, Director, since 2020
- Mr. Hiroshi AkitomoDirector of Development, Director, since 2005
- Mr. Hidetoshi HamamotoDirector of Research, Director, since 2011
- Ms. Keiko YamasakiDirector of Quality Management, Director, since 2002
- Mr. Kunio IwataniIndependent Director
- Ms. Sachiko MorikawaIndependent Director
- Ms. Noriko OshiroIndependent Director
- Mr. Yasushi YamazakiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medrx Co Ltd's ILTS technology uses ionic liquids for transdermal drug delivery.
- NCTS technology employs nano colloidization for enhanced drug absorption.
- The company focuses on reducing side effects and improving drug efficacy for patients.
Weaknesses
- Medrx Co Ltd has only 22 employees, limiting operational capacity.
- The company's headquarters in Higashikagawa-shi, JP, may restrict market access.
- Limited workforce size could hinder rapid product development and scaling.
Opportunities
- Expanding ILTS and NCTS technologies into new pharmaceutical markets.
- Growing demand for transdermal drug delivery systems in Health Care sector.
- Potential partnerships with larger pharmaceutical companies for market reach.
Threats
- Competition from established pharmaceutical firms in Health Care sector.
- Regulatory challenges in developing new transdermal drug formulations.
- Economic downturns affecting pharmaceutical industry investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.